Vertex Pharmaceuticals Inc Ma (VRTX) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019

Earnings Press Release
10-K Annual Report
10-K YoY Changes
Vertex Pharmaceuticals Inc Ma
Ticker: VRTX CIK: 875320

Vertex Reports Full-Year and Fourth-Quarter 2019 Financial Results

- Full-year 2019 total GAAP product revenues of $4.16 billion -

- Full-year 2019 total non-GAAP product revenues of $4.00 billion, a 32% increase compared to the full-year 2018 -

- Company provides full-year 2020 total product revenue guidance of $5.1 billion to $5.3 billion -

BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2019 and provided full-year 2020 financial guidance.

"In 2019, our differentiated strategy of investing in serial scientific innovation to create transformative medicines delivered remarkable performance. This was marked by the early approval of TRIKAFTA, the rapid progression of our pipeline in additional diseases and continued financial growth as we continued to treat more patients with our medicines worldwide," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. "This success is the culmination of many years of hard work to build a team, a pipeline and a company that we believe will discover, develop and commercialize transformative medicines for years to come."

Fourth-Quarter and Full-Year 2019 Financial Highlights



	Three Months Ended December 31,				%	Twelve Months Ended December 31,				%
	2019		2018		Change	2019		2018		Change
	(in millions, except per share amounts)					(in millions, except per share amounts)
GAAP Product revenues, net	$	1,413	$	868	63%	$	4,161	$	3,038	37%
Non-GAAP Product revenues, net^	$	1,257	$	868	45%	$	4,005	$	3,038	32%

GAAP Operating income	$	551	$	128	332%	$	1,198	$	635	89%
Non-GAAP Operating income	$	593	$	348	70%	$	1,786	$	1,112	61%

GAAP Net income ^^	$	583	$	1,551		$	1,177	$	2,097
Non-GAAP Net income	$	444	$	337	32%	$	1,389	$	1,059	31%

GAAP Net income per share - diluted ^^	$	2.23	$	5.97		$	4.51	$	8.09
Non-GAAP Net income per share - diluted	$	1.70	$	1.30	31%	$	5.33	$	4.08	31%

^Non-GAAP product revenues exclude $155.8 million related to ORKAMBI in the fourth quarter and full year ended December 31, 2019. Please refer to Note 4 for further information.
^^ GAAP Net income and GAAP Net income per share - diluted included a benefit from income taxes of approximately $1.5 billion in the fourth quarter and full year ended December 31, 2018 due to the release of Vertex's valuation allowance on the majority of its net operating losses and other deferred tax assets.

The following information was filed by Vertex Pharmaceuticals Inc Ma (VRTX) on Thursday, January 30, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Vertex Pharmaceuticals Inc Ma's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Vertex Pharmaceuticals Inc Ma.

Continue

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/875320/000087532020000007/a201910k-main.htm